Company intelligence / Profile preview

Sudimplant

Superior, Colorado, USAdnb.com ↗

Ownership: Private
Employees: ~8
Development stage: Other

Overview

Sudhin Biopharma has developed and commercialized the BioSettler platform—a patented inclined settler device—for efficient continuous biological manufacturing. The technology enables selective cell retention in perfusion bioreactors to achieve high-density cultures and is used in harvesting/purification of secreted products such as antibodies or viral vectors as well as concentration/harvesting of cell therapy products like CAR-T cells. The platform has been demonstrated with CHO perfusion bioreactors and tested for various applications including separation of β islet cells from iPSCs.

Therapeutic areas: Rare DiseasesImmunologyEndocrinologyOncology
Modalities: DeviceRecombinant proteinCell therapy
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Sudimplant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sudimplant.

Explore the full profile